Is ivonib a targeted drug? How to combine with other targeted drugs to improve efficacy?

Ivosidenib is an oral small molecule targeted drug specifically targeting tumor patients with isocitrate dehydrogenase 1 (IDH1) mutations. IDH1mutations lead to elevated levels of 2-hydroxyglutarate (2-HG) in the body, which hinders normal cell differentiation and promotes cancer development. Ivonib can inhibit the activity of IDH1 mutant protein, reduce the accumulation of 2-HG, thereby restoring cell differentiation ability , showing significant efficacy in the treatment of IDH1 mutation-related tumors such as acute myeloid leukemia (AML) and cholangiocarcinoma.

In order to improve the efficacy, ivonib is often used in combination with other targeted drugs or chemotherapy drugs. In the treatment of AML, ivonib can be combined with azacitidine (Azacitidine). Studies have shown that this combination can further inhibit cancer cell proliferation, improve the complete remission rate and prolong patient survival. In addition, for patients with relapsed or refractory AML, ivonib can also be used in combination with the BCL-2 inhibitor Venetoclax. This combination can enhance the apoptosis effect of tumor cells and improve the treatment response rate.

In the field of cholangiocarcinoma, ivonib can also be used in combination with other therapies. For example, after standard chemotherapy (such as gemcitabine + cisplatin), ivosidenib can be used as maintenance therapy to help delay disease progression and improve patients' progression-free survival (PFS). In addition, studies are exploring the combination of ivonib with immune checkpoint inhibitors, such as PD-1/PD-L1 antibodies, to further stimulate the immune system against IDH1 mutant tumors.

In general, ivonib, as an IDH1 targeted drug, has shown good efficacy in the treatment of various cancers, and has shown stronger anti-cancer ability in combination treatment regimens. In the future, with the advancement of more clinical studies, the combination strategy of ivonib with other targeted drugs, chemotherapy or immunotherapy is expected to provide better treatment options for patients with IDH1 mutations, increase survival rate and improve quality of life.

Reference link:https://www.tibsovo.com/